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Abstract
Background. Little information is available about the
long-term outcome of renal transplanted patients with idi-
opathic membranous nephropathy (MN).
Methods. The outcomes of 35 first renal transplants per-
formed between 1975 and 2008 in patients with MN were
compared with those of 70 controls transplanted in the same
period and matched for sex, age and source of donors.
Results. The mean post-transplant follow-up was 117 ±
86 months for MN patients and 123 ± 83 months for con-
trols. At 15 years, patient survival was 96% in patients
with MN and 88% in the controls (P = ns), while graft sur-
vival rates were respectively 40% and 69% (P = 0.06). MN
recurred in 12 patients (34%), namely in 4/8 (50%) pa-
tients who received the kidney from related living donors
and in 8/27 (29.6%) who received the kidney from a de-
ceased donor. Recurrence led to graft failure in six pa-
tients, all deceased donor kidney recipients, within 54 ±
33 months. The other six grafts are functioning 134 ±
73 months after transplantation. Patients with recurrence
were more frequently females (42% vs 4.3%, P = 0.02).
The recurrence occurred earlier (4.8 ± 3.0 vs 45.6 ±
46.9 months, P = 0.05), and there was a trend to develop
a higher proteinuria (7.1 ± 5.5 vs 3.67 ± 2.6 g/24 h, P =
0.1) in grafts eventually lost because of recurrence.
Conclusions. The long-term patient survival was similar in
renal transplant recipients with MN and in controls. The
graft survival was lower in MN patients than in controls,
although the difference was at borderline significance. Re-
currence occurred in one-third of the patients and caused
graft loss in half of them.
Keywords: membranous nephropathy; recurrent glomerulonephritis;
renal transplantation
Introduction
Membranous nephropathy (MN) is the most frequent cause
of idiopathic nephrotic syndrome (NS) in adults and may
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lead 40–50% of patients to end-stage renal disease (ESRD)
in the long term [1,2]. The disease may recur after trans-
plantation, but the impact of recurrence on the long term is
still poorly defined. From the first cases of recurrence of
MN on an allograft described [3,4] up to now, around 250
cases of renal transplants in patients with MN have been
reported [5–15].
The Renal Allograft Disease Registry [13] and the
Australian Registry [14] reported that MN was the third
most frequent type of glomerulonephritis resulting in
graft loss because of recurrence. The risk of recurrence
was 12.5% in the Australian Registry. However, the
overall incidence of graft loss at 10 years was not dif-
ferent in patients with MN and in those with other
types of renal disease (40.1% vs 45.8%) [14].
In several single-centre series, the post-transplant recur-
rence rate of MN ranged between 10% and 50% [5–8,10–
12,15]. This wide range of recurrence depends on the dif-
ferences in the number of patients evaluated, duration of
follow-up and indications to graft biopsy among the differ-
ent centres. The actuarial risk of graft loss in patients with
recurrent MN was estimated to be ∼50% at 10 years in a
previous review of the literature [10]. Probably due to the
low number of patients and/or to the short-term follow-up,
no definite predictors of recurrence were identified, and no
treatment proved to be effective in inducing remission of
recurrent MN.
The aims of this single-centre retrospective analysis
were (i) to compare the long-term patient and renal
allograft survival of MN patients with those of well-
matched controls, (ii) to compare the long-term compli-
cations in these two groups and (iii) to evaluate the rate,
the outcome and the predictors of recurrence in renal
transplant recipients with MN.
Materials and methods
Patients
Of 2053 renal transplants (1721 from deceased donors and 332 from liv-
ing donors) performed in our unit from July 1975 to July 2009, 35 (1.7%)
were performed on adults (>18 years) with ESRD due to biopsy-proven
MN. Eight of these patients received a graft from a living donor. Some of
the patients included in this study have been previously described by
Montagnino et al. [7].
Patients receiving a renal transplant in the same period (±3 months
before or after), matched for age (±5 years), gender and source of the
donor, were chosen as controls. Of 70 controls, 12 patients were carriers
of autosomal dominant polycystic kidney disease, 16 had biopsy-proven
glomerular diseases, 9 had a chronic non-biopsied glomerulonephritis, 2
had hypertensive nephrosclerosis, 18 had urological causes of ESRD, 2
had haemolytic uraemic syndrome, 3 had diabetic nephropathy and
8 had renal failure of unknown origin. In this last group, none of the pa-
tients had NS before the development of renal insufficiency.
Definitions
‘Recurrence’ was suspected due to the discovery of de novo proteinuria
and was confirmed by renal biopsy. The presence, at renal biopsy, of cap-
illary wall thickening at light microscopy associated with granular sube-
pithelial immune deposits of IgG and C3 in some cases confirmed the
diagnosis of recurrent membranous nephritis.
‘Biopsy policy’: Whenever an acute episode of renal dysfunction
of doubtful origin or persistent proteinuria >0.5 g/day developed, the
patient was submitted to graft biopsy.
‘Evaluation of renal biopsies’: All biopsies were evaluated by light mi-
croscopy and by immunofluorescence, and by electron microscopy when
the specimen was available.
‘Acute rejection’ was diagnosed on the basis of a double-checked in-
crease of 30% or more in plasma creatinine over the baseline not ex-
plained by other causes. The severity of rejection and the classification
of chronic lesions were scored retrospectively according to the recently
revised Banff classification [16].
‘Severe infections’: Infections requiring hospitalization.
Immunosuppression
Nine patients (26%) in the MN and 19 (27%) in the control group re-
ceived prednisone and cyclosporine (CsA). Four patients (11.4%) in the
MN and three in the control group (4.3%) received only CsA. Eleven MN
patients (31%) and 21 (30%) controls received prednisone, CsA and aza-
thioprine or mycophenolate mofetil (MMF). Eight MN patients (20%)
and 15 controls (21.4%) received prednisone, tacrolimus and azathioprine
or MMF. Three MN patients (8.5%) and eight controls (11.4%) received
prednisone and azathioprine. In the control group, four patients received
prednisone and sirolimus associated with CsA in three and with MMF
in one.
Acute cellular rejections were treated with intravenous methylpred-
nisolone pulses (MPP) therapy, and acute vascular rejections with anti-
thymocyte globulins.
Statistical analysis
The statistical package S-Plus was used to analyse the sample data.
Mean ± SD was used for descriptive analysis. t-test and non-parametric
Wilcoxon test were used to look at the differences between the two
groups of patients. Cross-tabulated data were analysed by chi-square
test, or by Fisher test when the expected cell count was less than five.
Survival curves were drawn using the Kaplan–Meier estimate and com-
pared using the log-rank test. Given the non-normal distribution of the
data, the impact of proteinuria on graft survival was evaluated by the
calculated median value for each patient (total 3288 measures).
Results
In Table 1, the main demographic characteristics of MN
patients and of controls are reported. The diagnosis of
MN was made 52.8 ± 62.6 months before reaching ESRD.
MN patients had been on dialysis for 51.3 ± 62.3 months
before transplantation.
Patient and graft survival
The mean post-transplant follow-up was 117 ± 86 months
for MN patients and 123 ± 83 for controls (P = ns).
The actuarial 15-year patient survival rates were 96% in
MN patients and 88% in controls (P = 0.6) (Figure 1). Two
patients in the MN group died (6%), one from sepsis and
the other one from myocardial infarction after a follow-up
of 34 and 216 months, respectively. In the control group,
eight patients died (11.4%) after a mean follow-up of
163 ± 126 months, two from sepsis, four from cardiac
failure and two from cancer. All deaths occurred with still
functioning grafts. Seventeen out of 35 grafts in MN
patients were lost (48%). The cause was recurrence of
MN in six patients (complicated by transplant glomerulo-
pathy in one), chronic rejection in three, unspecific scle-
rosing lesions in six, reduction of therapy due to Kaposi's
sarcoma in one and acute arterial graft thrombosis in the
last. Twenty graft failures occurred in the control group
(29%). Causes of graft failure were chronic rejection in
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12 patients, unspecific sclerosing lesions in 3, primary
non-functioning kidney in 1, recurrence of primary glo-
merular disease in 3 and acute arterial graft thrombosis
in 1.
The actuarial 15-year pure graft survival rates were 40%
in MN patients, and 69% in the control group (P = 0.06)
(Figure 2). Excluding the six grafts lost for recurrence, re-
nal survival of MN transplanted patients was 75% at
10 years and 53% at 15 years (data not shown).
Post-transplant complications
The number of delayed graft functions, of acute and
chronic rejections, of unspecific sclerosing lesions, of
patients with arterial hypertension, and of severe infec-
tions was not different between MN patients and controls
(Table 2).
Outcome of transplant patients with MN of the native
kidney
Among the 23 patients without recurrence, 12 never devel-
oped proteinuria during a mean follow-up of 153 ±
114.1 months after transplant. Two of these patients were
biopsied because of an increase in serum creatinine 4 and
11 months after transplant; biopsy showed an acute cellu-
lar rejection in the first patient and an acute cellular rejec-
tion associated with unspecific sclerosing lesions in the
second. Both patients lost the graft at 145 and 24 months
after transplant. Among the other 10 patients, one died
216 months after transplant from cardiac failure, and an-
other lost the graft 18 months after transplant due to acute
arterial graft thrombosis. In the remaining eight patients,
the grafts are still functioning at 179 ± 119.6 months after
transplant. The other 11 patients developed non-nephrotic
proteinuria at 71 ± 54 months after transplant and under-
went graft biopsies that were evaluated in all cases with
light microscopy and immunofluorescence and with elec-
tron microscopy in eight cases. Renal biopsy showed trans-
plant glomerulopathy in two cases, chronic rejection in
three (not evaluated with electron microscopy) and unspe-
cific sclerosing lesions in six. Two patients still have a
functioning graft at 43 and 195 months after transplant.
Eight patients lost their grafts at 206 ± 44 months, and
one died 34 months after transplant from sepsis.
Table 1. Demographic characteristics of renal transplant recipients with MN and controls
MN 35 grafts Controls 70 grafts P
Age (years) at transplant (mean ± SD) 39.5 ± 10.9 39.0 ± 10.2 ns
Sex (male/female) 29/6 58/12 ns
Living/deceased donors 8/27 16/54 ns
Length of dialysis, months (mean ± SD) 51.3 ± 62.3 46.2 ± 52.8 ns
CAPD/HD/preemptive transplant 4/30/1 12/57/1 ns
HCV positive/negative 7/28 11/53 ns
HBV positive/negative 5/30 6/63 ns
Follow-up post-transplant (mean ± SD) 117.2 ± 85.8 123.8 ± 83.4 ns
Nadir serum creatinine (mg/dL) 1.4 ± 0.4 1.6 ± 0.7 ns
MN, membranous nephropathy; CAPD, continuous ambulatory peritoneal dialysis; HD, haemodialysis.
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Fig. 1. Kaplan–Meier estimates of patient survival in renal transplanted patients with membranous nephropathy (solid line) and in controls
(dashed line).
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The last 12 patients (34%) developed recurrence of
MN at 26.2 ± 38.8 months after transplantation (range
1.9–126 months) which was confirmed by graft biopsy
(Table 3) evaluated with electron microscopy in seven
cases. The follow-up of recurrent and non-recurrent patients
was not different (94.5 ± 68.3 vs 129.1 ± 92.87 months,
P = ns). Six out of the 12 recurrent grafts (50%) were
lost 54 ± 33 months after transplant due to recurrence
in five patients and to recurrence complicated by trans-
plant glomerulopathy in the last patient. The pure graft
survival at 10 years was lower in recurrent patients
(44%) than in non-recurrent patients (65%), but it was
similar at 15 years (44% vs 40%) (Figure 3). Patients
who lost their grafts had an earlier recurrence of MN
versus those who maintained graft function (4.8 ± 3.0 vs
45.6 ± 46.9 months, P = 0.05) and also showed a higher
proteinuria at the time of renal biopsy (7.1 ± 5.5 vs 3.67 ±
2.6 g/24 h, P = 0.1).
Of the eight patients with MN who received the kidney
from a living donor, four had recurrence (50%) versus
eight out of the 27 (29.6%) receiving their kidney from a
deceased donor (P = ns). None of the four living related
grafts that recurred was lost versus six out of eight de-
ceased donor grafts (P = 0.06).
The role of proteinuria in graft function
Due to the above mentioned higher proteinuria in MN pa-
tients who lost the graft due to recurrence, the value of pro-
teinuria as predictor of graft loss was tested in the
following groups of patients:
(a) MN (1.01 ± 2.12 g/24 h) vs controls (0.36 ± 0.5 g/
24 h), P = 0.044
(b) MN with (2.35 ± 3.25 g/24 h) vs those without (0.31 ±
0.42 g/24 h) recurrence, P = 0.003
Pts at risk 5 years 10 years 15 years 20 years
pts with MN 825 14 2
controls 652 34 19
0
20
40
60
80
100
0 105 15 20
pts with MN controls
p=0.06222
82%
90%
69%
58%
40%
 69%
Fig. 2. Kaplan–Meier estimates of renal survival probability censored for death in renal transplanted patients with membranous nephropathy (solid line)
and in controls (dashed line).
Table 2. Main complications after kidney transplantation
MN 35 grafts Controls 70 grafts P
Number of pts with delayed graft function 6 (17%) 11 (16%) ns
Number of pts with acute rejections 17 (48.5%) 31 (44%) ns
Vascular rejections 0 2
Cellular rejections 4 13
Clinical acute rejections 13 16
Number of pts with chronic rejectiona 5 (14%) 4 (6%) ns
Number of pts with unspecific sclerosing lesions 7 (20%) 14 (20%) ns
Number of pts with arterial hypertension 35 (100%) 57 (81%) ns
Number of pts with severe infections 15 (43%) 26 (37%) ns
Number of pts with Kaposi sarcoma 3 (8.5%) 1 (1.4%) ns
Number of pts with neoplasiab 2 (6%) 2 (3%) ns
pts, patients.
aIncluding transplant glomerulopathy.
bIn membranous nephropathy.
Breast cancer, one patient; lymphoma, one patient; in controls: gastric cancer, one patient; hepatocarcinoma, one patient.MN, membranous nephropathy.
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(c) MN patients who lost the graft for any reason (1.75 ±
2.78 g/24 h) vs MN patients with functioning graft
(0.22 ± 0.26 g/24 h), P = 0.025
(d) Controls who lost the graft (0.78 ± 1.91 g/24 h) vs
controls with functioning graft (0.19 ± 0.22 g/24 h),
P = 0.0016
(e) All (MN ± controls) grafts lost (1.24 ± 2.38 g/24 h) vs
functioning grafts (0.19 ± 0.23 g/24 h), P = 0.005
These results confirmed the predictive values of protein-
uria for graft survival.
Treatment of recurrences
In one patient, at diagnosis of recurrence continued with
the basal immunosuppressive therapy, ESRD eventually
developed 104 months after transplant (Table 3).
Table 3. Patients with recurrence of MN in renal transplantation
At diagnosis of recurrence Last observation
Pts Donor Sex
Time of
recurrence
Time of
T. biopsy
S.Creat
mg/dL
U.Prot
g/24 h
Therapy at
transplant
Therapy at
recurrence
Follow-up
months
S.Creat
mg/dL
U.Prot
g/24 h(months)
1 (CA) Deceased F 1.9 2.6 1.36 17.28 Pred.TAC.MMF ACE-i ARB RTX PLX 40 ESRD 13
2 (MF) Deceased M 2.2 6.3 2 3.5 Pred.TAC.AZA ACE-i 20 ESRD 4.18
3 (PD) Deceased M 3 4.2 1.7 4.1 Pred, CsA, AZA ACE-i 22 ESRD 18
4 (BG) Deceased F 4.8 8.6 0.8 5.5 Pred, CsA None 104 ESRD 8.3
5 (BG) Deceased M 8 18.8 2.2 9.3 Pred, CsA, AZA MPP ACE-i 73 ESRD 2.75
6 (ML) Deceased F 9 24.2 0.8 4.6 Pred.TAC.MMF MPP Cy 67 ESRD 2.4
7 (SF) Deceased M 61.5 61.5 1 2.58 Pred.TAC.MMF ACE-i ARB 80 1.2 0.2
8 (ME) Living M 66.5 66.5 1.7 2 Ster.CsA ACE-i MPP 230 1.6 0.15
9 (GD) Living M 126.1 130.3 1.98 8.6 Pred.CsA ACE-i MPP Cy 166 2.4 0.3
10 (GL) Living F 4 5.9 0.9 3.6 Pred.TAC.MMF ACE-i ARB RTX 30.4 1.2 1.2
11(PS) Living F 7.5 7.6 1.1 4 Pred.TAC.MMF ACE-i 118 1.2 0.07
12 (CE) Deceased M 20.2 31.8 1.1 1.24 CsA ACE-i 184 2.1 0.5
Pts, patients; S.Creat, serum creatinine; U.Prot, urinary protein; PLX, plasmapheresis; ACE-i, ACE inhibitor; Cy, cyclophosphamide; ESRD, end-stage
renal disease; MPP, methylprednisolone pulses; Pred, prednisone; CsA, cyclosporine; AZA, azathioprine; TAC, tacrolimus; MMF, mycophenolate.
Pts at risk 5 years 10 years 15 years 20 years
pts without recurrence 616 11 2
pts with recurrence 08 3 2
0
20
40
60
80
100
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pts without recurrence
pts with recurrence
87%
74%
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Fig. 3. Kaplan–Meier estimates of renal survival probability censored for death in renal transplanted patients without recurrence (solid line) and in
those with recurrence of membranous nephropathy (dashed line).
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In three out of the five patients treated with angiotensin-
converting enzyme (ACE) inhibitors [associated with an-
giotensin receptor blockers (ARB) in one], proteinuria
completely remitted, while in the other two patients, pro-
teinuria persisted with progressive deterioration of renal
function.
In two other patients, ACE inhibitors were associated
with three MPP, one patient achieved remission; in the sec-
ond, NS persisted, and the patient eventually developed
ESRD.
Two patients were treated for 6 months with MPP and
prednisone alternated with cyclophosphamide [17] associ-
ated with ACE inhibitors in one. In this last patient, NS
progressively remitted. The second patient achieved partial
and transient remission of proteinuria, and then, NS re-
curred associated with a progressive worsening of graft
function due to a super-imposed transplant glomerulopathy.
Two other patients treated with ACE inhibitors received
rituximab (four weekly infusions in one and only one in-
fusion in the second associated with seven plasma ex-
changes). The first patient achieved partial remission,
and the second progressed to ESRD.
Discussion
In this study, we have reported the long-term outcome of
35 MN patients submitted to renal transplant and compared
with a matched control group. The mean follow-up of our
MN transplant patients was of 9.7 years, the longest re-
ported to date to the best of our knowledge. The Australian
Registry reported that the actuarial renal allograft survival
at 10 years was similar in the 81 patients transplanted
because of MN (40.1%) and in the 1505 transplanted pa-
tients with other types of renal disease (14). In our experi-
ence, the pure graft survival at 10 and at 15 years was lower
in patients with MN than in controls; the difference was not
significant, probably due to the small number of patients.
Efforts to identify clinical factors that would predict the
risk for developing recurrence of MN have not been suc-
cessful to date. The Renal Allograft Disease Registry re-
ported that the post-transplant recurrence of MN was
more frequent in males [13]. In none of the single-centre
series was sex associated with MN recurrence [6,10,15].
Rather, we found that recurrence was significantly more
frequent in females. However, these data should be seen
with caution due to the small number of transplant patients
with MN in this study.
It is still unclear if patients receiving a living related kid-
ney are at higher risk of recurrence. Some old studies sug-
gested that MN is more likely to recur in living donor
grafts than in cadaveric grafts perhaps as a result of a fa-
milial predisposition to the disease [6,18]. In contrast, in
the combined Lyon-Louvain Medical School series, recur-
rence was equally frequent in deceased and in living grafts
[10], while Dabade et al. [15] observed that, among pa-
tients with recurrence, there were a numerically higher
number of deceased donor kidneys. In this study, we found
that recurrence occurred in half of living related patients vs
30% of deceased kidney recipients, but the number of pa-
tients was too small for any firm conclusion to be made.
The time of recurrence was not different between living
Table 4. Demographic, clinical and laboratory characteristics of patients with MN who relapsed and those who did not
Grafts with recurrent MN, 12 Non recurrent grafts, 23 P
Age at diagnosis of MN of the recipient (years) mean ± SD 25.1 ± 15.6 28.4 ± 9.0 0.43
Age at tx (years) mean ± SD 37.6 ± 11.8 40.4 ± 10.5 0.48
Sex of the recipient (male/female) 7/5 22/1 0.02
Months between diagnosis of MN and ESRD (months) mean ± SD 110.5 ± 62.8 90.8 ± 62.9 0.38
Duration of dialysis (months) mean ± SD 46.2 ± 55.9 54.0 ± 66.4 0.73
Type of dialysis HD/CAPD/pre-emptive transplant 9/2/1 21/2/0 0.27
Follow-up post-tx (months) mean ± SD 94.5 ± 68.3 129.1 ± 92.87 0.26
Deceased/living donors 8/4 19/4 0.52
HCV positive (yes/no) 2/10 5/18 0.93
HBV positive (yes/no) 1/11 4/19 0.83
Induction with basiliximab (n) 5 (42%) 2 (8.7%) 0.07
Calcineurin inhibitors therapy (yes/no) 12/0 20/3 0.51
Triple immunosuppression (n) 10 18 0.92
Nadir serum creatinine, mg/dL mean ± SD 1.2 ± 0.5 1.5 ± 0.4 0.06
Arterial hypertension (n) 12 23 0.80
Acute rejection (n) 3 12 0.24
Chronic rejection grafts (n) 1 4 0.83
Unspecific sclerosing lesions (n) 0 7 0.09
Number of patients with infections 2 13 0.06
Final serum creatinine, mg/dL mean ± SD 1.8 ± 0.7 1.58 ± 0.64 0.35
Final proteinuria, g/24 h mean ± SD 0.46 ± 0.68 0.68 ± 1.4 0.61
Number of lost kidneys 6 (50%) 11 (50%) 0.81
tx, transplant; ESRD, end-stage renal disease; CAPD, continuous ambulatory peritoneal dialysis; HD, haemodialysis.
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related and deceased kidney recipients. However, although
recipients of living related donors had a high rate of recur-
rence, the evolution of their transplant was better than that
of cadaver recipients. Therefore, transplants from a living
donor should not be contraindicated in these patients.
In this series, 34% of patients developed graft recur-
rence of MN in a mean of 5years after transplantation, al-
though 8 out of 12 patients developed recurrence within
the first year after transplant. Recently, [15] an even higher
histological recurrence of MN (8 of 19 patients, 42%) was
reported after a mean follow-up of 13 months (range 2–
61 months). These 19 patients were submitted to surveil-
lance graft biopsies at time 0, 4, 12 and 60 months after
renal transplant. The initial clinical manifestations of re-
current MN were mild, with a mean proteinuria of
800 mg/day, and three patients had proteinuria within the
normal range. In one patient, proteinuria never developed
>1 year of follow-up. Our patients were not submitted to
surveillance graft biopsies, and we cannot exclude that
some of our non-recurrent patients may have developed
a clinically asymptomatic histological recurrence.
The ominous prognostic value of proteinuria on graft
survival is well known [19]. For this reason, we evaluated
the impact of proteinuria in our study population (MN plus
controls) which confirmed its relevance upon graft evolu-
tion. In our patients with recurrence of MN, those who lost
their graft had higher proteinuria, although the difference
was not significant, probably due to the small number of
patients in our series.
However, 11 out of 23 non-recurrent patients developed
proteinuria during the follow-up, and graft biopsy evaluat-
ed with light microscopy and immunofluorescence in all
cases and electron microscopy in eight cases did not allow
the diagnosis of recurrence of MN. We cannot exclude that
some of the cases not evaluated with electron microscopy
had subepithelial electron-dense deposits in addition to the
other histological pictures, although none of these patients
developed overt NS during a long observation. The other
12 patients never developed proteinuria during a mean fol-
low-up of >12 years. This long observation time without
proteinuria would reasonably exclude the probability of a
misdiagnosed recurrence.
Six of the 12 recurrent grafts are still functioning after a
mean follow-up of 11 years, while the other 6 grafts (50%)
were lost because of recurrence within 5 years. Therefore,
in total, 6 of 35 (17%) MN patients lost their allograft be-
cause of MN recurrence. This percentage is higher than the
6–9% reported by Briganti et al. [14] and Odorico et al.
[11], but is similar to the 25% reported by Cosyns et al.
[10]. Of interest, our data showed that early recurrence is
an ominous prognostic sign. On the other hand, if the risk
of graft failure caused by recurrence is excluded, the long-
term graft survival of patients with MN was similar to that
of patients with other diseases in this study as well as in
other studies [9,10].
Treatment of recurrent MN is difficult. ACE inhibitors,
ARB and statins are generally used to attenuate the risk of
complications related to NS. In this series, most patients
were treated with inhibitors of the renin–angiotensin sys-
tem, and a complete remission of proteinuria was seen in
three of them, although we cannot exclude that our patients
entered a spontaneous remission. However, even if possi-
ble, spontaneous remission occurs very rarely in patients
with post-transplant recurrence [12]. Our results are at
odds with the recent report of the Mayo Clinic, in which
proteinuria increased over time despite the early use of an-
giotensin blockade [15]. It is open to discussion whether
the preemptive use of ACE inhibitors/ARB is valuable in
preventing the progression of proteinuria or in treating it.
A prospective study is warranted to clarify the role of ACE
inhibitors/ARB. There is no convincing evidence that glu-
cocorticoids, calcineurin inhibitors or purine synthesis in-
hibitors are of benefit in recurrent MN. In particular, in
this study as well as in our previous report [7], calcineurin
inhibitors, which are effective in native MN [20], seem
not to be able to prevent the recurrence of MN in renal
transplant recipients. In keeping with our data, cyclospor-
ine or tacrolimus was not found to prevent recurrences in
the experience of other authors [10,15]. Anecdotal cases
of response were reported with the so-called Ponticelli
regimen alternating glucocorticoids and an alkylating
agent [21]. Two of our patients were treated with this reg-
imen, and a partial remission was obtained in both; how-
ever, one of them progressed to ESRD 10 months later
because of a super-imposed transplant glomerulopathy.
Rituximab has been found to be successful in several
cases of MN on native kidneys with non-advanced histo-
logical lesions [22,23]. Success has been reported in sin-
gle cases with rituximab [24,25]. In a recent report, eight
recipients with recurrent post-transplant MN and a mean
proteinuria of 4.4 g/day were treated with rituximab.
Twelve months post-rituximab, 75% of patients had either
partial or complete remission which maintained up to the
24th month in all but one patient. Post-treatment biopsies
showed resorption of electron-dense immune deposits in
6/7 cases [26]. We treated two patients with rituximab;
one did not show any improvement, while the second ob-
tained persistent partial remission.
In conclusion, although treatment of recurrent MN is
still far from satisfactory, some measures seem to be
helpful. In the absence of contraindications—such as renal
artery stenosis, severe hyperkalaemia or severe anaemia—
inhibition of the renin–angiotensin system should be
offered to all patients. In cases of no response, a cyclical
treatment with steroids/alkylating agents might obtain
remission at least in a few patients. However, such a treat-
ment is contraindicated in patients who have received
heavy immunosuppression and should be associated with
a concomitant reduction in other immunosuppressive
drugs. Rituximab together with a reduction of immuno-
suppressive regimen may be tried early in patients with
NS, before any progressive decline of renal graft function
ensues. Once again, however, we recommend caution in
patients heavily immunosuppressed in order to avoid
severe and even life-threatening infections. Early treat-
ment is probably more successful therefore in all pa-
tients with a history of MN, and particularly, in those
receiving a kidney from a living related donor, a proto-
col biopsy should be performed at 3–6 months in order
to recognize at an early stage recurrent lesions before
the occurrence of severe proteinuria renders treatment
inefficacious.
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